Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study.
作者信息
Joly Pascal
机构信息
Department of Dermatology, Rouen University Hospital, Centre de référence des maladies bulleuses autoimmunes and INSERM U1234, Normandie University, Rouen, France.
Department of Dermatology, Rouen University Hospital, Centre de référence des maladies bulleuses autoimmunes and INSERM U1234, Normandie University, Rouen, France.
出版信息
J Am Acad Dermatol. 2022 Feb;86(2):494-497. doi: 10.1016/j.jaad.2021.10.034. Epub 2021 Oct 29.
Abstract
摘要
相似文献
1
Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study.自身免疫性水疱性皮肤病患者中新冠病毒病的发病率和严重程度：一项全国性研究。
J Am Acad Dermatol. 2022 Feb;86(2):494-497. doi: 10.1016/j.jaad.2021.10.034. Epub 2021 Oct 29.
2
Autoimmune blistering diseases: incidence and treatment in Croatia.自身免疫性水疱病：克罗地亚的发病率和治疗方法。
Dermatol Clin. 2011 Oct;29(4):677-9. doi: 10.1016/j.det.2011.07.003. Epub 2011 Aug 15.
3
Management of autoimmune bullous diseases in France: a nationwide network of 30 centers.法国自身免疫性大疱性疾病的管理：一个由 30 个中心组成的全国性网络。
Dermatol Clin. 2011 Oct;29(4):659-62. doi: 10.1016/j.det.2011.06.017.
4
Impact of COVID-19 in patients with autoimmune bullous diseases: Report from an international registry.新型冠状病毒肺炎对自身免疫性大疱性疾病患者的影响：一项国际登记报告
J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1189-e1191. doi: 10.1111/jdv.19242. Epub 2023 Jun 21.
5
Impact of COVID-19 on autoimmune blistering diseases.COVID-19 对自身免疫性水疱病的影响。
Clin Dermatol. 2021 May-Jun;39(3):359-368. doi: 10.1016/j.clindermatol.2021.01.007. Epub 2021 Feb 2.
6
Association between COVID-19 vaccination and autoimmune bullous diseases: a random coincidence or rare event.2019冠状病毒病疫苗接种与自身免疫性大疱性疾病之间的关联：随机巧合还是罕见事件。
J Eur Acad Dermatol Venereol. 2022 Sep;36(9):e665-e666. doi: 10.1111/jdv.18202. Epub 2022 May 18.
7
Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.新型冠状病毒肺炎大流行期间自身免疫性大疱性疾病管理的最新国际专家建议。
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e412-e414. doi: 10.1111/jdv.17207. Epub 2021 Mar 19.
8
Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany.德国下弗兰肯地区自身免疫性大疱性疾病发病率的前瞻性分析。
J Dtsch Dermatol Ges. 2009 May;7(5):434-40. doi: 10.1111/j.1610-0387.2008.06976.x. Epub 2009 Jan 19.
9
Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.表皮下自身免疫性大疱性皮肤病：概述、流行病学和相关性。
Immunol Res. 2018 Feb;66(1):6-17. doi: 10.1007/s12026-017-8975-2.
10
An autoimmune subepidermal blistering skin disease in a dog? The odds are that it is not bullous pemphigoid.
Vet Dermatol. 2014 Aug;25(4):316-8. doi: 10.1111/vde.12152.
引用本文的文献
1
Rituximab for the Management of an Australian Cohort of Treatment Refractory Mucous Membrane Pemphigoid.利妥昔单抗用于治疗澳大利亚一组难治性黏膜类天疱疮患者
Australas J Dermatol. 2025 Aug;66(5):e271-e278. doi: 10.1111/ajd.14523. Epub 2025 May 16.
2
Outcomes and risk factors of COVID-19 in patients with bullous pemphigoid: a cross-sectional study.大疱性类天疱疮患者感染新型冠状病毒肺炎的结局及危险因素：一项横断面研究
Front Immunol. 2025 Apr 25;16:1568801. doi: 10.3389/fimmu.2025.1568801. eCollection 2025.
3
Optimizing Pemphigus Management With Rituximab and Short-Term Relapse Predictors.使用利妥昔单抗优化天疱疮管理及短期复发预测因素
JAMA Dermatol. 2025 Apr 1;161(4):399-405. doi: 10.1001/jamadermatol.2024.6130.
4
The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid.以患者为中心的药物研发在天疱疮和类天疱疮中的重要性。
J Invest Dermatol. 2023 Oct;143(10):1868-1871. doi: 10.1016/j.jid.2023.03.1673. Epub 2023 May 5.
5
Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia.在2019冠状病毒病大流行期间使用免疫抑制疗法治疗天疱疮的考量，重点关注利妥昔单抗：来自澳大利亚单一中心经验的病例报告
Front Med (Lausanne). 2023 Mar 14;10:1149742. doi: 10.3389/fmed.2023.1149742. eCollection 2023.
6
Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine.新冠疫情期间的自身免疫性大疱性疾病：2022年利妥昔单抗与疫苗最新进展
Front Med (Lausanne). 2023 Jan 19;10:1112823. doi: 10.3389/fmed.2023.1112823. eCollection 2023.
7
Off-Label Uses of Rituximab in Dermatology.利妥昔单抗在皮肤科的非标签使用
Curr Dermatol Rep. 2022;11(4):209-220. doi: 10.1007/s13671-022-00375-4. Epub 2022 Oct 6.
8
Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies.COVID-19疫情期间的天疱疮：感染风险、疫苗反应及管理策略
J Clin Med. 2022 Jul 8;11(14):3968. doi: 10.3390/jcm11143968.
9
Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.利妥昔单抗治疗黏膜性类天疱疮：109 例患者的回顾性单中心研究及长期随访
Front Immunol. 2022 Jun 30;13:915205. doi: 10.3389/fimmu.2022.915205. eCollection 2022.
10
Adverse outcome and severity of COVID-19 in patients with autoimmune bullous diseases: A historical cohort study.自身免疫性大疱性疾病患者 COVID-19 的不良结局和严重程度：一项历史性队列研究。
Dermatol Ther. 2022 Sep;35(9):e15672. doi: 10.1111/dth.15672. Epub 2022 Jul 21.
本文引用的文献
1
Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.新型冠状病毒肺炎大流行期间自身免疫性大疱性疾病管理的最新国际专家建议。
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e412-e414. doi: 10.1111/jdv.17207. Epub 2021 Mar 19.
2
Treatment considerations for patients with pemphigus during the COVID-19 pandemic.COVID-19大流行期间天疱疮患者的治疗考量
J Am Acad Dermatol. 2020 Jun;82(6):e235-e236. doi: 10.1016/j.jaad.2020.04.005. Epub 2020 Apr 10.
3
Epidemiology of Covid-19.新型冠状病毒肺炎的流行病学
N Engl J Med. 2020 May 7;382(19):1869. doi: 10.1056/NEJMc2005157. Epub 2020 Mar 27.
4
Incidence and Mortality of Pemphigus in France.法国天疱疮的发病率和死亡率。
J Invest Dermatol. 2019 Feb;139(2):469-473. doi: 10.1016/j.jid.2018.07.042. Epub 2018 Sep 17.
5
Prediction of survival for patients with bullous pemphigoid: a prospective study.大疱性类天疱疮患者生存情况的预测：一项前瞻性研究。
Arch Dermatol. 2005 Jun;141(6):691-8. doi: 10.1001/archderm.141.6.691.
Zotero 插件